"An attorney who just reads off a script spewing random facts at the jury will likely cause the jurors to check out," writes Kenton H. Steele, Esq.
Growing evidence supports the existence of an intermediate metastatic disease state.
Experts outline their clinical approach to identifying treatment failure in patients on initial pharmacologic treatment for OAB and strategies for subsequent treatment selection.
Dr. Freedland closes his discussion by highlighting remaining unmet needs in mCRPC treatment and providing some clinical pearls for community oncologists treating patients with the disease.
In the first article of this series, Juan Montoya, MD, discusses advances in perirectal spacing in the treatment of prostate cancer.
Prostate cancer experts highlight some closing thoughts and exciting research in progress on prostate cancer imaging.
"Now is the time for programs to leverage their existing telehealth platforms and practices for trainee education while continuing to serve patients," the authors write.
Dr Chamie shares advice for community urologists treating patients with MIBC.
Concepcion is editor-in-chief of Urology Times' sister publication, Urologists in Cancer Care.
"We feel a more appropriate approach would be to retain true Gleason 6 as a cancer of extremely low metastatic potential requiring close follow-up," write Harris et al.
In the second article of this series, Ryan A. Hankins, MD, and Sean P. Collins, MD, PhD, discuss multidisciplinary care practices in prostate cancer, with a focus on communication across specialties.
The drug-coated balloon catheter system is being compared with a sham device in a double-blinded randomized trial.
In this companion article, Sandip M. Prasad, MD, MPhil, from the Morristown Medical Center in New Jersey discusses the historic use of radical nephroureterectomy and provides an overview of his clinical experience using kidney-sparing approaches for LG UTUC.
Experts summarize how the use of PSMA-PET imaging has impacted the field to date and share their hopes for the future.
Rebekah Bernard, MD, provides tips for improving interactions with patients who are angry.
When a miscoded procedure is the result of substantial negligence or fraud, it can be detrimental to a medical practice or physician.
Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Recent research has revived the controversy regarding the role of cytoreductive nephrectomy in this setting.
Here are seven ways texting can improve healthcare revenue and decrease costs.
"Now is the time for programs to leverage their existing telehealth platforms and practices for trainee education while continuing to serve patients," the authors write.
The application is specifically for use of enzalutamide in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence and is supported by data from the phase 3 EMBARK trial.
While online reviews are critical in any industry, patient expectations are simply different when it comes to health care.
The phase 2 study explored the combination of the PD-1 inhibitor toripalimab and chemotherapy as neoadjuvant treatment for patients with upper tract urothelial carcinoma.
University Hospitals Urology Institute is excited to announce that this coming fall, the department is hosting 2 educational courses in cutting-edge urologic specialties: female sexual health and gender care.
The symposium brings together clinicians devoted to solving the disease of cancer and the many challenges associated with it.
"We feel a more appropriate approach would be to retain true Gleason 6 as a cancer of extremely low metastatic potential requiring close follow-up," write Harris et al.
Findings from the PEACE-1 trial published in the Lancet showed that adding abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved overall survival in patients with de novo metastatic castration-sensitive prostate cancer.
"HIFU allows us to treat where we want and not where we don’t," writes Jennifer Linehan, MD.
Patient data is so valuable — and smaller providers are more vulnerable — that hackers are increasingly targeting physician groups.